Form 4: KalVista Pharmaceuticals Acquired by Chiesi Farmaceutici

Director Brian J.G. Pereira reports the cancellation and cash-out of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Summary

• KalVista Pharmaceuticals, Inc. has been acquired by Chiesi Farmaceutici S.p.A. via a merger with a subsidiary, Skyline Merger Sub, Inc.
• The acquisition was completed on June 11, 2026, with the company becoming a wholly owned subsidiary of Chiesi.
• Shareholders received a cash consideration of $27.00 per share.
• Outstanding stock options with exercise prices below $27.00 were cancelled and converted into the right to receive a cash payment equal to the spread between the merger price and the exercise price.
• Options with exercise prices equal to or greater than $27.00 were cancelled for no consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the final administrative step of a previously announced acquisition rather than new operational news.

Positives

• The merger provides liquidity to shareholders at a fixed cash price of $27.00 per share.
• Director stock options were successfully converted into cash payments based on the merger consideration.

Negatives

• Stock options with exercise prices of $27.00 or higher were cancelled without any consideration.
• The company is no longer a publicly traded entity following the merger.

Risks

• The company has ceased to be an independent public entity, eliminating future upside potential for public shareholders.

Future Outlook

The company is now a wholly owned subsidiary of Chiesi Farmaceutici S.p.A. and no longer provides independent public guidance.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated April 29, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large global pharmaceutical companies acquiring specialized biotech firms to bolster their rare disease and specialty medicine pipelines.

Comparison to Industry Standards

• The $27.00 per share cash offer represents a standard exit strategy for biotech firms reaching the commercialization or late-stage development phase.
• The treatment of 'out-of-the-money' options (cancelled for no consideration) is consistent with standard M&A practices in the pharmaceutical sector.

Legal Proceedings

• The company was acquired via a merger agreement with Chiesi Farmaceutici S.p.A.

Stakeholder Impact

• Shareholders have been cashed out at $27.00 per share.
• Option holders received cash payments for vested and unvested options where the exercise price was below the merger consideration.

Next Steps

• Delisting of KalVista Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

KalVista Pharmaceuticals, Chiesi Farmaceutici, Merger, Acquisition, Form 4, Stock Options, Takeover